Actively Recruiting
Development of an AI-Driven Dynamic Prediction and Precision Stratification System for Coronary Non-Target Lesion Progression After Percutaneous Coronary Intervention in China
Led by China-Japan Friendship Hospital · Updated on 2025-12-31
12000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
C
China-Japan Friendship Hospital
Lead Sponsor
P
Peking Union Medical College
Collaborating Sponsor
AI-Summary
What this Trial Is About
Coronary heart disease is a major cause of death worldwide, and while percutaneous coronary intervention (PCI) helps improve outcomes, patients still face significant long-term risks from the progression of non-target lesions (NTLs). Current tools are not enough to predict which patients will experience this progression. This multicenter cohort study in China aims to develop an artificial intelligence (AI) system that uses clinical data, blood biomarkers, and coronary imaging from over 52,000 patients to better predict and stratify the risk of NTL progression after PCI. The goal is to enhance personalized management and improve long-term prognosis. The study collects comprehensive multimodal data, including clinical profiles, multi-omics blood biomarkers, and coronary imaging, from patients who are scheduled for or have undergone PCI. Researchers will identify specific biomarkers linked to NTL progression and use machine learning methods to build a risk assessment and early-warning system. The study also plans to classify patients into metabolic and imaging-based subtypes to guide precision management and secondary prevention strategies. Participants will provide baseline plasma samples and agree to follow-up assessments over 12 months. The research team will monitor outcomes such as myocardial infarction or the need for revascularization related to NTL progression using these data. The study's primary outcome focuses on a composite endpoint of NTL progression-related events, with secondary measures including qualitative and quantitative data on lesion progression. This observational study involves no experimental treatment but closely tracks patient health and disease progression to inform future risk prediction tools.
CONDITIONS
Brief Title
AI-Driven Dynamic Prediction of Non-Target Lesion Progression After PCI: A Chinese Multicenter Cohort Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Scheduled for or have undergone percutaneous coronary intervention (PCI)
- Able to provide a baseline plasma sample
- Provided informed consent to participate
You will not qualify if you...
- Pregnant or breastfeeding
- Severe liver or kidney dysfunction
- Active autoimmune disease
- Missing critical data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Procedure day
Participants undergo percutaneous coronary intervention (PCI), a minimally invasive procedure to restore coronary blood flow by treating the obstructive lesion.
1 visit (in-person)
Duration - 12 months
Participants are monitored for up to 12 months after PCI to observe non-target lesion progression and related clinical outcomes.
Visits may occur periodically for assessments up to 12 months
Trial Site Locations
Total: 1 location
1
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
F
Fang Wang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here